Friday 6 November 2026
Export GMED’s income statement to Excel — free account
Globus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
70.68
10.76
−13.21%
Follow GMED
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
21.94 | 19.81 | 19.90 | 18.09 |
P/S ratio |
4.02 | 3.76 | 3.39 | 3.20 | |
P/FCF ratio |
20.75 | 19.75 | 14.50 | 13.45 | |
P/Operating CF |
47.49 | 57.63 | 50.88 | 37.88 | |
P/B ratio |
2.58 | 2.46 | 2.24 | 2.09 | |
Price to Tangible BV |
4.93 | 4.53 | 4.05 | 3.76 | |
EV/Sales |
4.12 | 3.84 | 3.48 | 3.28 | |
EV/EBITDA |
15.47 | 14.27 | 11.72 | 11.06 | |
EV/Operating CF |
16.07 | 15.28 | 12.01 | 11.14 | |
EV/FCF |
21.28 | 20.14 | 14.86 | 13.81 | |
Quick Ratio |
2.61 | 2.83 | 2.78 | 1.43 | |
Current Ratio |
4.26 | 4.56 | 4.62 | 4.30 | |
Net Debt/EBITDA |
(2.27) | (2.86) | (2.36) | — | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.56 | 0.61 | 0.60 | 0.59 | |
Operating CF/Net income |
1.77 | 1.63 | 1.38 | 1.88 | |
Capex/Depreciation |
(0.61) | (0.57) | (0.48) | 0.00 | |
Research and Development Expense of Revenue |
4.38% | 4.80% | 4.60% | 4.52% | |
Selling, General and Administrative Expense of Revenue |
38.54% | 39.19% | 36.32% | 0.00% | |
Intangible Assets out of Total Assets |
0.41 | 0.40 | 0.39 | 0.38 | |
Share Based Compensation of Revenue |
1.38% | 1.66% | 1.69% | 1.54% | |
Graham Net Nets |
0.12 | 0.13 | 0.14 | 0.14 | |
Graham Number |
55.03 | 58.50 | 56.16 | 57.71 | |
Earnings Yield |
4.56% | 5.05% | 5.02% | 5.53% | |
Free Cash Flow Yield |
4.82% | 5.06% | 6.90% | 7.43% | |
Revenue per Share |
6.11 | 5.61 | 5.85 | 5.69 | |
Operating CF per Share |
1.84 | 1.50 | 1.55 | 1.98 | |
Capex per Share |
(0.34) | (0.29) | (0.25) | (0.30) | |
Free Cash Flow per Share |
1.50 | 1.20 | 1.31 | 1.68 | |
Cash per Share |
4.12 | 4.65 | 4.41 | 0.00 | |
Shareholders Equity per Share |
33.82 | 34.96 | 35.31 | 35.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
33.82 | 34.96 | 35.31 | 35.75 | |
Free Cash Flow |
202.31 | 162.75 | 176.57 | 224.84 | |
Working Capital |
1,627.11 | 1,715.66 | 1,736.17 | 1,674.03 | |
Capital Expenditures |
(46.28) | (39.61) | (33.17) | (40.39) | |
Net Current Asset Value |
1,396.10 | 1,490.88 | 1,495.86 | 1,450.02 | |
EV/EBIT |
25.24 | 22.31 | 17.10 | 15.17 | |
Capex to Sales |
0.06 | 0.05 | 0.04 | 0.05 | |
Price to Operating Income |
24.60 | 21.87 | 16.69 | 14.78 | |
| Other line items | |||||
Average Receivables |
661.00 | 636.78 | 699.70 | 706.04 | |
Average Payables |
86.99 | 88.40 | 97.02 | 97.33 | |
Average Inventory |
709.26 | 718.10 | 791.51 | 797.84 | |
Average Assets |
5,277.26 | 5,075.35 | 5,224.67 | 5,311.92 | |
Average Common Equity |
4,375.29 | 4,410.19 | 4,532.14 | 4,597.54 |
Columns are period end dates · fundamentals updated 5 Nov 2026